Tannergren C - Search Results

1

Regional Intestinal Permeability of Three Model Drugs in Human.

Dahlgren D, Roos C, Lundqvist A, Abrahamsson B, Tannergren C, Hellström PM, Sjögren E, Lennernäs H. Dahlgren D, et al. Among authors: tannergren c. Mol Pharm. 2016 Sep 6;13(9):3013-21. doi: 10.1021/acs.molpharmaceut.6b00514. Epub 2016 Aug 18. Mol Pharm. 2016. PMID: 27504798 Clinical Trial.

2

The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique.

Tannergren C, Knutson T, Knutson L, Lennernäs H. Tannergren C, et al. Br J Clin Pharmacol. 2003 Feb;55(2):182-90. doi: 10.1046/j.1365-2125.2003.01722.x. Br J Clin Pharmacol. 2003. PMID: 12580990 Free PMC article.

3

Enantioselective transport and CYP3A4-mediated metabolism of R/S-verapamil in Caco-2 cell monolayers.

Engman H, Tannergren C, Artursson P, Lennernäs H. Engman H, et al. Among authors: tannergren c. Eur J Pharm Sci. 2003 May;19(1):57-65. doi: 10.1016/s0928-0987(03)00065-4. Eur J Pharm Sci. 2003. PMID: 12729862

4

Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo.

Petri N, Tannergren C, Holst B, Mellon FA, Bao Y, Plumb GW, Bacon J, O'Leary KA, Kroon PA, Knutson L, Forsell P, Eriksson T, Lennernas H, Williamson G. Petri N, et al. Among authors: tannergren c. Drug Metab Dispos. 2003 Jun;31(6):805-13. doi: 10.1124/dmd.31.6.805. Drug Metab Dispos. 2003. PMID: 12756216

5

Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine.

Tannergren C, Petri N, Knutson L, Hedeland M, Bondesson U, Lennernäs H. Tannergren C, et al. Clin Pharmacol Ther. 2003 Nov;74(5):423-36. doi: 10.1016/S0009-9236(03)00238-8. Clin Pharmacol Ther. 2003. PMID: 14586383 Clinical Trial.

6

St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism.

Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernäs H. Tannergren C, et al. Clin Pharmacol Ther. 2004 Apr;75(4):298-309. doi: 10.1016/j.clpt.2003.12.012. Clin Pharmacol Ther. 2004. PMID: 15060508 Clinical Trial.

7

Transport characteristics of fexofenadine in the Caco-2 cell model.

Petri N, Tannergren C, Rungstad D, Lennernäs H. Petri N, et al. Among authors: tannergren c. Pharm Res. 2004 Aug;21(8):1398-404. doi: 10.1023/b:pham.0000036913.90332.b1. Pharm Res. 2004. PMID: 15359574

8

The effect of pancreatic and biliary depletion on the in vivo pharmacokinetics of digoxin in pigs.

Tannergren C, Evilevitch L, Pierzynowski S, Piedra JV, Weström B, Erlwanger K, Tatara M, Lennernäs H. Tannergren C, et al. Eur J Pharm Sci. 2006 Nov;29(3-4):198-204. doi: 10.1016/j.ejps.2006.06.009. Epub 2006 Jun 30. Eur J Pharm Sci. 2006. PMID: 16935480

9

Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment.

Tannergren C, Bergendal A, Lennernäs H, Abrahamsson B. Tannergren C, et al. Mol Pharm. 2009 Jan-Feb;6(1):60-73. doi: 10.1021/mp800261a. Mol Pharm. 2009. PMID: 19183105

10

Increased understanding of intestinal drug permeability determined by the LOC-I-GUT approach using multislice computed tomography.

Knutson T, Fridblom P, Ahlström H, Magnusson A, Tannergren C, Lennernäs H. Knutson T, et al. Among authors: tannergren c. Mol Pharm. 2009 Jan-Feb;6(1):2-10. doi: 10.1021/mp800145r. Mol Pharm. 2009. PMID: 19248228 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

42 results

Search Page

Filters